Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 11/20 | 0.48 |
| ▸ | KDR | P35968 | 8/20 | 0.47 |
| ▸ | TEK | Q02763 | 4/20 | 0.47 |
| ▸ | FLT3 | P36888 | 3/20 | 0.45 |
| ▸ | KIT | P10721 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | LYN | P07948 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | BLK | P51451 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | LTK | P29376 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819439 | 0.88 | IDH1 (0.49) | KDRFLT3 | |
| SCHEMBL2818316 | 0.87 | KDR (0.46) | BRAFKDRTEK | |
| SCHEMBL2812619 | 0.85 | KCNMA1 (0.52) | BRAFKDRFLT3KITLCK | |
| SCHEMBL2816988 | 0.81 | ADORA2A (0.45) | — | |
| SCHEMBL2816509 | 0.79 | MEN1 (0.47) | — | |
| SCHEMBL3999791 | 0.76 | KMT2A (0.52) | — | |
| SCHEMBL3993087 | 0.76 | SMN1; SMN2 (0.50) | — | |
| SCHEMBL2812011 | 0.76 | MEN1 (0.45) | — | |
| SCHEMBL2816860 | 0.76 | ADORA2B (0.43) | — | |
| SCHEMBL2813498 | 0.75 | KDR (0.54) | BRAFKDRTEKFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2193122-B1 | IMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-08-03 | — | — | EP | claimed |
| US-20100249132-A1 | IMIDAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-30 | — | — | US | claimed |
| EP-2193122-B1 | IMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249132-A1 | IMIDAZOLE DERIVATIVES | SDHA, SDHB, TPD52L2 | BRAF 481/4885KDR 1879/4885TEK 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.